Xanthones and their antidepressant uses

A technology of xanthone and compound, applied to xanthone compound and its application field in antidepressant drugs, can solve problems such as large toxic and side effects, and achieve the effect of good antidepressant activity

Inactive Publication Date: 2016-05-11
NANJING TECH UNIV +2
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far, most of the drugs used in the clinical treatment of depression are accompanied by relatively large toxic and side effects. The search for antidepressants with good curative effect and low side effects has always been the direction of researchers' efforts

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Xanthones and their antidepressant uses
  • Xanthones and their antidepressant uses
  • Xanthones and their antidepressant uses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: 1,3-Dihydroxy-6-methyl-9H-xanthone

[0026]

[0027] Measure 100ml of phosphorus oxychloride, weigh 30g of zinc chloride, add to a 250ml three-neck flask, stir well and heat to 60°C, add 15.2g of 4-methylsalicylic acid and 18.4g of phloroglucinol after reacting for 1h (all dried), after the reaction temperature is stable, slowly heat to 70°C, take a sample after 3.5 hours of reaction, and detect by TLC (petroleum ether: ethyl acetate = 2:1), the reaction is complete, stop the reaction, pour it after cooling completely Add about 1500ml of ice water, stir, let stand, filter with suction, wash until neutral, filter cake is dried and separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1), to obtain 10.8g of light yellow powder, product The rate is 44.6%.

[0028] ESI-MSm / z:241.0[M - ]. 1 HNMR (CDCl 3 +DMSO-d 6 , 500MHz) δ: 12.89(1H, s), 8.05(1H, d, J=8.5Hz), 7.21(1H, s), 7.16(1H, d, J=8Hz), 6.37(1H, d, J=8Hz) 2Hz), 6.26 (1H,...

Embodiment 2

[0029] Example 2: 1,3-Dihydroxy-7-methyl-9H-xanthone

[0030]

[0031] 15.2g of 5-methylsalicylic acid and 18.4g of phloroglucinol were obtained according to the synthetic method of Example 1 to obtain 14.6g of light yellow powder with a yield of 60.3%.

[0032] ESI-MSm / z:241.0[M - ]. 1 HNMR (CDCl 3 +DMSO-d 6 , 500MHz) δ: 12.87(1H, s), 10.41(1H, s), 7.96(1H, d, J=1Hz), 7.54(1H, dd, J=8.5, 2Hz), 7.34(1H, d, J =8.5Hz), 6.37(1H, d, J=2Hz), 6.23(1H, d, J=2Hz), 2.47(3H, s).

Embodiment 3

[0033] Example 3: 1,3-dihydroxy-5-methoxy-9H-xanthone

[0034]

[0035] 16.8g of 4-methoxysalicylic acid and 18.4g of phloroglucinol were obtained according to the synthetic method of Example 1 to obtain 9.4g of light yellow powder with a yield of 36.4%.

[0036] ESI-MSm / z:256.9[M - ]. 1 HNMR (DMSO-d 6 , 500MHz) δ: 12.80(1H, s), 11.05(1H, s), 7.64(1H, dd, J=8, 1.5Hz), 7.54(1H, d, J=8Hz), 7.36(1H, d, J=8Hz), 6.40 (1H, d, J=2Hz), 6.22 (1H, d, J=2Hz), 3.97 (3H, s).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses xanthone compounds and their use in depression resistance. The xanthone compounds are compounds shown in the structural formula (I) or their pharmaceutically acceptable salts. An experiment proves that the xanthone compounds have good depression-resistant activity and a part of the xanthone compounds have depression-resistant activity superior to that of venlafaxine. Therefore, the xanthone compounds and their pharmaceutically acceptable salts can be used for preparation of depression-resistant drugs.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a class of xanthone compounds and their application in antidepressants. Background technique [0002] Depression is a common affective disorder mental illness, characterized by significant and persistent low mood. Depression seriously affects the quality of life of patients and brings them a heavy economic burden. According to a survey released by the World Health Organization in 2004, depression ranks third in the global burden of disease, accounting for 4.3% of the total global burden of disease. It is predicted that its prevalence will be second only to heart disease by 2020. bit. The pathogenesis of depression is very complicated, and there are many incentives, which brings many difficulties to the development of antidepressant drugs. [0003] According to the clinical research results, various theories have been formed to explain the pathogenesis of depression. At presen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D311/86A61K31/352A61K31/4025A61K31/5377A61P25/24
CPCC07D311/86
Inventor 石金城樊明夏超刘媛张桂森祁超陈国广
Owner NANJING TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap